AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01001572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 capsule or tablet taken orally once daily
Study NCT03375723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information on anatomy and physiology, and breathing technique
Description: The patients in the treatment group receive information about what acute PE is regarding anatomy and physiology, a review of what causes the respiratory associated pain in acute PE and also a review of the breathing technique to manage their respiratory associated pain. The given information is standardized and the patient also receives written information with both text and pictures. Patients in the treatment group will meet the physiotherapist at day 1, 2 and the patients also has an opportunity to see the physiotherapist or talk to her at the phone if there are any questions concerning the study.
Study NCT03375723 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care treatment
Description: Usual care treatment given to patients with respiratory associated pain in acute PE, which is treatment with analgesics. The information on anatomy and physiology in acute PE is the usual information given by the physician at the ward that the patient is treated.
Study NCT04373018 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite
Description: Sodium hypochlorite irrigant will be used during biomechanical preparation.
Study NCT04373018 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Chlorhexidine irrigant will be used during biomechanical preparation.
Study NCT04373018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine + Hydrogen peroxide
Description: Chlorhexidine + Hydrogen peroxide irrigant will be used during biomechanical preparation.
Study NCT01958554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Study NCT01186367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linear Aerobic Training
Description: The 130-180 minutes/week will be achieved via either 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes per/session (± 10 minutes).
Study NCT01186367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nonlinear Aerobic Training
Description: The 130-180 minutes/week will be achieved via 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes/ per session (+/- 10 minutes).
Study NCT01186367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Stretching
Description: All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
Study NCT01186367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test (CPET)
Study NCT01186367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Complete blood count
Study NCT02701179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lignocaine 1% concentration solution
Study NCT02701179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lignocaine 2% concentration solution
Study NCT01706731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual (TAU)is defined as the routine care provided to each individual patient at the geriatric psychiatry clinic of Maharaj Nakorn Chiang Mai Hospital.
Study NCT01706731 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual (TAU)is defined as the routine care provided to each individual patient at the geriatric psychiatry clinic of Maharaj Nakorn Chiang Mai Hospital.
Study NCT01706731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: Cognitive behavioral therapy(CBT)includes psychoeducational components combined with cognitive interventions targeted at challenging negative automatic thoughts.
Study NCT02065349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP8477
Description: oral
Study NCT02065349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT04303429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX/XELOX/Capecitabine
Description: Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.
Study NCT02752490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liberal use of maternal oxygen
Description: Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by ACOG10 at the discretion of the primary nurse or physician
Study NCT02752490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indicated use of maternal oxygen
Description: Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
Study NCT02130674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipeptiven
Description: two groups: group 1: continuous infusion for 24 hours group 2: continuous infusion for 5 days
Study NCT01941927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (GSK1120212)
Description: Trametinib is a highly selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity.
Study NCT01941927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2141795
Description: GSK 2141795 is an ATP competitive subnanomolar pan-AKT inhibitor. In order to measure the true potency of GSK 2141795, potency (Ki\*) values were determined in a filter binding assay using lower enzyme concentrations (0.1, 0.7, and 0.2 nM for human AKT1, AKT2, and AKT3, respectively). Using a sandwich ELISA, GSK 2141795 inhibited phosphorylation of GSK-3β in BT474 and LNCaP cell lines with EC50 values of 143 and 34 nM, respectively. Since phosphorylation of GSK-3β can be modulated by other enzymes (PKA, PKC, and RSK),cellular activity of GSK 2141795 was evaluated using a phospho-PRAS40 ELISA. GSK 2141795 inhibited the phosphorylation of PRAS40 with EC50 values of 39 and 55 nM for BT474 and LNCaP cells, respectively.
Study NCT04501939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirmtuzumab
Description: Cycle 1, Day 1 \& 15 - 600mg Cycle 2, Day 1 to Cycle 6, Day 1 - 600mg
Study NCT04501939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 400mg PO daily from cycle 1 day 1 for 6 cycles of 28 days.
Study NCT04304053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment and prophylaxis
Description: Cases will be offered a therapeutic regimen hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7~Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7.
Study NCT04304053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Public Health measures
Description: Isolation of patient and contact tracing as per national guidelines.
Study NCT04304053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Public Health measures
Description: Isolation of patient and contact tracing as per national guidelines.
Study NCT00848237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (HALO Ablation Systems)
Description: Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.
Study NCT00981162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO
Study NCT00981162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO
Study NCT00981162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study NCT00981162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative study
Study NCT00981162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative study
Study NCT02981862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CaptHPV method
Description: 20 ml of blood sample will be made before the beginning of all treatment. This blood sample will be sent to the CERBA Laboratory for analysis.~In parallel, a standard anatomopathological and virological analysis will be carried out from a biopsy or from a tumor sample by the Tumor Biology Unit at Lorraine Institute of Oncology~The results of both analyzes will be compared blindly.
Study NCT04062981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate
Description: An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
Study NCT02454530 — intervention group
Intervention type: BIOLOGICAL
Intervention: Nivestim®
Study NCT05113420 — intervention group
Intervention type: DRUG
Intervention: Detralex
Description: Diosmin+ Hesperidin
Study NCT05113420 — intervention group
Intervention type: DRUG
Intervention: Troxevasin
Description: Troxerutin
Study NCT01094808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: FDA approved medication (capsules) at 75 mg and 200 mg doses
Study NCT01603498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8mg
Study NCT01603498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 40mg
Study NCT00681213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoral/Sirolimus
Study NCT00804648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate in Sorbate
Description: 0.5%
Study NCT04353518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suspension of heat killed (autoclaved) Mycobacterium w
Description: Subjects randomized to Test arm will receive intraderma Mw in divided doses at least 2 cm away from first injection site in the deltoid region.
Study NCT04353518 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo arm will receive intraderma Placebo in divided doses at least 2 cm away from first injection site in the deltoid region.
Study NCT04057612 — intervention group
Intervention type: OTHER
Intervention: Esophagus temperature monitoring
Description: Measuring core temperature by esophageal stethoscope
Study NCT04057612 — intervention group
Intervention type: OTHER
Intervention: Carotid artery temperature monitoring
Description: Measuring temperature on skin near to carotid artery using 3M™ Bair Hugger™ temperature monitoring system
Study NCT01429415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate Sandoz
Description: Each treatment will utilize 600 mg (1.2 mL) of Magnesium Sulfate Sandoz
Study NCT01429415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride , USP PPC
Description: Intervention: The control group will receive Sodium Chloride , USP PPC (1.2 mL hypertonic 5.5% saline with 5 mg Salbutamol - GlaxoSmithKline/Pharmascience
Study NCT00691860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesh (Ultrapro ®)
Description: In the mesh group, the mesh was placed in the sublay position, above the peritoneum and the posterior rectus sheath of the rectus abdominis muscles, with a minimum of 5 cm of mesh around the colostomy
Study NCT00691860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional sigmoid end colostomy
Description: Patients receiving conventional sigmoid end colostomy, without mesh
Study NCT00691860 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional sigmoid end colostomy
Description: Patients receiving conventional sigmoid end colostomy, without mesh
Study NCT04108793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy exercises
Description: The intervention group will receive an extended home-based rehabilitation program twice a week continued for 3 months (12 weeks) after discharge funded by the study.
Study NCT01094808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT01094808 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bowel preparation
Description: Polyethylene glycol electrolyte solution bowel preparation
Study NCT01094808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowel preparation
Description: Polyethylene glycol electrolyte solution bowel preparation
Study NCT01774292 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation with injection of liquid in the cuff
Study NCT01774292 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endotracheal intubation with injection of liquid in the cuff
Study NCT02546310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0009936
Study NCT02546310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HTL0009936 matching placebo
Study NCT04062370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Patients will receive intravitreal injection of Ranibizumab 0.5 mg (1+PRN or 3+PRN) according to the study until month 6. Then, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN after month 6.
Study NCT04062370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Patients will receive intravitreal injection of Ranibizumab 0.5 mg (1+PRN or 3+PRN) according to the study until month 6. Then, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN after month 6.
Study NCT04062370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser photocoagulation
Description: After month 6, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN according the re-randomization at month 6.
Study NCT04062370 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser photocoagulation
Description: After month 6, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN according the re-randomization at month 6.
Study NCT01559701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00345439
Description: 5-80 mg twice-a-day for 12 months
Study NCT04220138 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anterior chamber illumination in cataract surgery
Description: This will be a prospective interventional case series, patients with cataract and poor red reflex will undergo phacoemulsification assisted by anterior chamber illumination to overcome the problem of poor red reflex.
Study NCT01939093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.
Study NCT01939093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.
Study NCT01939093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B1-6-12
Description: All subjects will be given the Institute's medication regimen, including vitamin B1-6-12 1 tablet three times a day after meals during the whole study period.
Study NCT01939093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B1-6-12
Description: All subjects will be given the Institute's medication regimen, including vitamin B1-6-12 1 tablet three times a day after meals during the whole study period.
Study NCT01939093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stugeron
Description: All subjects will be given the Institute's medication regimen, including stugeron 1 tablet three times a day after meals during the whole study period.
Study NCT01939093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stugeron
Description: All subjects will be given the Institute's medication regimen, including stugeron 1 tablet three times a day after meals during the whole study period.
Study NCT01242254 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of KH902
Description: 0.5 mg 2.0 mg once per 4 weeks during fixed dosing phase once as needed during extended treatment phase
Study NCT00150345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole (Vfend)
Description: voriconazole, early treatment
Study NCT00150345 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: voriconazole (Vfend)
Description: voriconazole, deferred treatment
Study NCT04399980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mavrilimumab
Description: Treatment infusion
Study NCT04399980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo infusion
Study NCT02967484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: 1. Huo Xue San Feng acupuncture method: Patients will recieve the acupuncture treatment,choose the bilateral point:Renying(ST9),Hegu(L14),Taichong(LR3),Quchi(LI11),Zusanli(ST36).~2. Routine care for ischemic stroke :patients will recieve the acupuncture treatment,choose the point:Neiguan(PC6),Renzhong(10),Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40).~3. Drugs: Antihypertensive drugs.Patients will be treated 1 of 5 type of antihypertensive drugs,include ARB、ACEI、βreceptor blocker,CCB,Diuretic.~The time of therapy will consist of 6 times per week in Continuous treatment phase(1st-6th week after enrollment) and 3 times per week(once every other day) in Consolidation treatment phase(7th-tewlve week after enrollment)
Study NCT01138696 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: KOOS, IKDC, SF-36, Lysholm, Tegner, VAS),
Study NCT01138696 — intervention group
Intervention type: OTHER
Intervention: RX
Description: X-rays and clinical investigation of the knee 20 years after surgery
Study NCT02713113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex reversal of neuromuscular blockade
Study NCT02254044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bivatuzumab mertansine
Study NCT04029428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 90Y-DOTATATE
Description: Total activity of 90Y DOTATATE, 4x3.7GBq (14.8 GBq). Single session of i.v. infusion of 90Y DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 90Y DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
Study NCT04029428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (177Lu-DOTAOTyr3)Octreotate
Description: Total activity of 177Lu DOTATATE, 4x5.55GBq (22.2 GBq). Single session of i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
Study NCT04029428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)
Description: Total activity of 90Y DOTATATE and 177Lu DOTATATE, 4x3.7GBq (14.8 GBq 50% each 90Y and 177Lu). Single session of i.v. infusion of 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
Study NCT02518165 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Proprietary spearmint extract
Description: Water extracted spearmint extract
Study NCT02518165 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline Cellulose
Study NCT00993863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose
Study NCT00993863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5859 30 mg
Description: single dose
Study NCT00993863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5859 100 mg
Description: single dose
Study NCT00993863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5859 200 mg
Description: single dose
Study NCT00993863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen 400 mg
Description: single dose
Study NCT01457404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Therapy
Description: Individual or group ICBT, approx. 12 sessions, one session per week
Study NCT01457404 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Individual or group therapy as usual within the SATP or PTSD clinics at the PVAMC